ProNAi Therapeutics, a licensee of RNAi specialist Marina Biotech ($MRNA), reported positive results from its so-called DNAi-based candidate PNT2258 for non-Hodgkin lymphoma. Using Marina's Smarticles delivery tech, the results from the Phase II trial shows meaningful therapeutic outcomes and a durable clinical response, according to the company. It is the first DNAi-based therapeutic being tested while RNAi is more commonly used to shut down genes. Release